For the interim period of the fiscal year ending March 2027, net sales were 22,148 million yen (Year-over-Year (YoY) +2.4%), operating income was 1,490 million yen (YoY +38.2%), ordinary income was 1,586 million yen (YoY +34.3%), and net income attributable to owners of parent for the interim period was 957 million yen (YoY +19.2%). Increased revenue and profit were driven by the clinical testing and ICT businesses. Full-year forecasts for 2027 remain unchanged. Dividend forecasts are maintained and the number of outstanding shares at fiscal year-end is unchanged.<\/p>\n","protected":false},"comment_status":"open","ping_status":"closed","template":"","meta":{"Ticker":"","DATE":"","longName":"","company_name_ja":"","fullTimeEmployees":0,"address":"","phone":"","website":"","industry":"","sector":"","regularMarketPrice":0,"financialCurrency":"","marketCap":0,"fiftyTwoWeekLow":0,"fiftyTwoWeekHigh":0,"epsTrailingTwelveMonths":0,"epsForward":0,"bookValue":0,"totalRevenue":0,"OperatingIncome":0,"operatingMargins":0,"NetIncome":0,"profitMargins":0,"ebitda":0,"trailingPE":0,"forwardPE":0,"priceToBook":0,"returnOnEquity":0,"recommendationMean":0,"recommendationKey":"","targetMeanPrice":0,"numberOfAnalystOpinions":0,"analyst_earnings_data":"","dividendRate":0,"dividendYield":0,"payoutRatio":0,"totalEsg":0,"environmentScore":0,"socialScore":0,"governanceScore":0,"title":"","providerPublishTime":"","link":"","longBusinessSummary":"","longBusinessSummary_ja":"","quarterly_revenue":0,"quarterly_net_income":0,"quarterly_operating_profit":0,"enterprise_value":0,"price_fetched_at":"","company_officer_1_name":"","company_officer_1_title":"","company_officer_2_name":"","company_officer_2_title":"","company_officer_3_name":"","company_officer_3_title":"","company_officer_4_name":"","company_officer_4_title":"","company_officer_5_name":"","company_officer_5_title":"","company_officers_update_time":"","get_dividend_history_year1":0,"get_dividend_history_year2":0,"get_dividend_history_year3":0,"get_dividend_history_year4":0,"get_dividend_history_year5":0,"get_dividend_history_year6":0,"get_dividend_history_year7":0,"get_dividend_history_year8":0,"get_dividend_history_year9":0,"get_dividend_history_year10":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"jir_stock_code":"4671","jir_company_name":"FALCO HOLDINGS Co., Ltd.","jir_importance":"\u2605\u2605\u2605\u2605\u2606","jir_publication_date":"2026-11-06","jir_source_link":"https:\/\/japanir.jp\/wp-content\/uploads\/2026\/11\/4671-20261106-01.pdf","jir_short_summary":"For the interim period of the fiscal year ending March 2027, net sales were 22,148 million yen (Year-over-Year (YoY) +2.4%), operating income was 1,490 million yen (YoY +38.2%), ordinary income was 1,586 million yen (YoY +34.3%), and net income attributable to owners of parent for the interim period was 957 million yen (YoY +19.2%). Increased revenue and profit were driven by the clinical testing and ICT businesses. Full-year forecasts for 2027 remain unchanged. Dividend forecasts are maintained and the number of outstanding shares at fiscal year-end is unchanged.","jir_summary":"### Summary of Results\nDuring the interim period, increased sales and profits in the clinical testing and ICT businesses resulted in net sales of 22,148 million yen, operating income of 1,490 million yen, ordinary income of 1,586 million yen, and net income attributable to owners of parent of 957 million yen. In clinical testing, stronger sales activities and improved productivity contributed, while in ICT the expansion in the number of cloud-based service deployments contributed. Progress was also made on regulatory approvals and consideration for insurance coverage related to genomics. The full-year forecast for the current fiscal year remains unchanged from the previous announcement. There are no major revisions to the dividend forecast.\n\n### Outlook and Capital Allocation\nThe solid interim performance was driven by growth in clinical testing and ICT, which are the Company\u2019s growth drivers. Under the long-term vision FALCO VISION 2030 and the mid-term plan FALCO INNOVATION 2026, the Company will continue to strengthen both its foundation and growth areas. There is no change to the most recently disclosed dividend forecast, and no additional information on treasury stock acquisitions is provided at this time.","jir_financial_highlights":"Net Sales: 22,148 (YoY +2.4%)\nOperating Income: 1,490 (YoY +38.2%)\nOrdinary Income: 1,586 (YoY +34.3%)\nNet Income Attributable to Owners of Parent: 957 (YoY +19.2%)\nInterim Net Income per Share: 96.10 (YoY)","jir_category":"","jir_hashtags":"#FALCO_HOLDINGS, #EarningsRelease","jir_key_figures":"Net Sales: 22,148 million yen\nOperating Income: 1,490 million yen\nNet Income Attributable to Owners of Parent (Interim): 957 million yen","jir_meta_title":"FALCO HOLDINGS Co., Ltd. Second Quarter Financial Results for FY2027 | Net Sales 22,148 million yen, Operating Income 1,490 million yen","jir_meta_description":"Summary of FALCO HOLDINGS Co., Ltd.'s Q2 FY2027 financial results: net sales 22,148 million yen, operating income 1,490 million yen, ordinary income 1,586 million yen, net income 957 million yen. Growth driven by clinical testing and ICT businesses; full-year outlook unchanged.","jir_og_title":"FALCO HOLDINGS Co., Ltd.\uff5cSecond Quarter Financial Results for FY2027","jir_og_description":"Growth in clinical testing and ICT businesses contributed to net sales of 22,148 million yen, operating income of 1,490 million yen, and net income of 957 million yen. Full-year forecast remains unchanged.","jir_og_image_url":"\/assets\/og\/company-general_ir.jpg","jir_chart_data_collection":"[]","ir_related_company":57353,"ir_release_date":"","ir_type":"","ir_is_new":false,"ir_document_url":"","jir_ir_type":"financial_summary","footnotes":""},"sector":[],"importance":[],"class_list":["post-143913","ir_release","type-ir_release","status-publish","hentry"],"yoast_head":"\n